REQUEST FOR THE PROPOSAL No. 54/2020-YKL-40 – Ex-vivo study on therapeutic efficacy of 3 YKL40 inhibitors and reference compound – update of 05.10.2020 and 12.10.2020

The order is carried out as a part of the project titled:
– YKL-40: “DEVELOPMENT OF A FIRST-IN-CLASS SMALL MOLECULE DRUG CANDIDATE FOR CANCER TREATMENT THROUGH YKL 40 INHIBITION” (POIR.01.01.01-00-0552/16)

co-financed by the European Union Funds and because of the competitiveness principle.

We hereby look for Contractor ready to perform the service:

Ex-vivo study on therapeutic efficacy of three YKL40 inhibitors and reference compound on cell and tissue IPF models.

54_2020_RFQ

54_2020_Appendices_1_2_3_4

On Ocober 5, 2020 the Ordering Party introduces changes to the order description and the deadline for submitting offers. Changes are marked in red. The Appendices have not been changed.

54_2020_RFQ_update_05.10.2020

On October 12, 2020, the Ordering Party introduces a change regarding the extension of the deadline for submitting offers. The change is marked in green. The Appendices have not been changed.

54_2020_RFQ_update_12.10.2020

Kinga KazimierczakREQUEST FOR THE PROPOSAL No. 54/2020-YKL-40 – Ex-vivo study on therapeutic efficacy of 3 YKL40 inhibitors and reference compound – update of 05.10.2020 and 12.10.2020